Ipamorelin

Origin and Development

Developed as part of pharmaceutical research into growth hormone secretagogues, originally under Novo Nordisk. Development as a therapeutic candidate was not carried through to approval. It was designed to be more selective than earlier secretagogues, stimulating growth hormone release with comparatively little effect on cortisol and prolactin.

Mechanism as Understood in the Literature

Agonist at the ghrelin receptor (GHS-R1a) in the pituitary, prompting release of endogenous growth hormone. Its distinguishing characteristic in the literature is selectivity: earlier growth hormone secretagogues tended to also raise cortisol and prolactin, and ipamorelin was designed to minimize that.

Research Status

Some early human work exists, largely from the period when it was under pharmaceutical development, including studies in postoperative ileus. It did not progress to approval, and there is no substantial modern clinical trial program. [VERIFY BEFORE PUBLICATION: FDA 503A/503B bulk drug substances status for ipamorelin.] [REPLACE/COMPLETE: postoperative ileus development program citation needs exact title, journal, and trial outcome.]

Regulatory status

Not FDA-approved for any indication. Prohibited in competitive sport under World Anti-Doping Agency rules.

Commonly Confused With

Frequently sold as a blend with CJC-1295, to the point that many buyers encounter the two only as a combination product. They are different molecules acting on different receptors: ipamorelin acts on the ghrelin receptor, CJC-1295 on the GHRH receptor. Also distinct from GHRP-2 and GHRP-6, which act on the same receptor as ipamorelin but with less selectivity.

How This Compound Is Marketed

Vendors in this market commonly market this compound for growth hormone support, recovery, sleep, and body composition, usually sold alongside CJC-1295. These are vendors’ marketing claims, not VialReport’s. VialReport does not verify, evaluate, or endorse them, and nothing on this page is medical, dosing, or purchasing advice or a recommendation to use any compound. See “Research status” above for what the published literature actually establishes.

It is usually sold alongside CJC-1295.

Analytical Profile

Five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular weight approximately 711 Da. Contains non-standard amino acids, which gives it a distinctive analytical signature. Blends present a harder analytical problem than single compounds, since two active ingredients must be resolved and quantified separately.

Stability and Handling

Supplied lyophilized. Stability depends on molecular form, formulation, moisture, container closure, temperature, and reconstitution conditions, and published data may not apply to research-channel material.

Key Literature

01 Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
02 [COMPLETE: postoperative ileus development program citation needs exact title, journal, and trial outcome.]

Reports for Ipamorelin

No reports for this compound yet.

Get notified when new reports publish.

What chain-of-custody documentation looks like